Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTN8NRXK)

• DOT Name: Neuropeptides B/W receptor type 1 (NPBWR1)
• Synonyms: G-protein coupled receptor 7
• Gene Name: NPBWR1
• Related Disease:
  Neuralgia
  Prostate cancer
  Prostate carcinoma
  Prostate neoplasm
  High blood pressure
• UniProt ID: NPBW1_HUMAN
• Pfam ID: PF00001
• Sequence:
  MDNASFSEPWPANASGPDPALSCSNASTLAPLPAPLAVAVPVVYAVICAVGLAGNSAVLY
  VLLRAPRMKTVTNLFILNLAIADELFTLVLPINIADFLLRQWPFGELMCKLIVAIDQYNT
  FSSLYFLTVMSADRYLVVLATAESRRVAGRTYSAARAVSLAVWGIVTLVVLPFAVFARLD
  DEQGRRQCVLVFPQPEAFWWRASRLYTLVLGFAIPVSTICVLYTTLLCRLHAMRLDSHAK
  ALERAKKRVTFLVVAILAVCLLCWTPYHLSTVVALTTDLPQTPLVIAISYFITSLSYANS
  CLNPFLYAFLDASFRRNLRQLITCRAAA
• Function: Interacts specifically with a number of opioid ligands. Receptor for neuropeptides B and W, which may be involved in neuroendocrine system regulation, food intake and the organization of other signals. Has a higher affinity for neuropeptide B.
• Tissue Specificity: Found in cerebellum and frontal cortex. Detected at high levels in hippocampus, amygdala and trachea; at moderate levels in fetal brain, pituitary gland and prostate. Not in caudate, accumbens, kidney or liver. Also detected at high levels in lung carcinoma.
• KEGG Pathway: Neuroactive ligand-receptor interaction (hsa04080)
• Reactome Pathway:
  G alpha (i) signalling events (R-HSA-418594)
  Peptide ligand-binding receptors (R-HSA-375276)

Molecular Interaction Atlas (MIA) of This DOT

5 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Neuralgia	DISWO58J	Strong	Altered Expression	[1]
Prostate cancer	DISF190Y	Strong	Biomarker	[2]
Prostate carcinoma	DISMJPLE	Strong	Biomarker	[2]
Prostate neoplasm	DISHDKGQ	Strong	Posttranslational Modification	[2]
High blood pressure	DISY2OHH	moderate	Biomarker	[3]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Neuropeptides B/W receptor type 1 (NPBWR1).	[4]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Neuropeptides B/W receptor type 1 (NPBWR1).	[5]

1 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
QUERCITRIN	DM1DH96	Investigative	QUERCITRIN increases the expression of Neuropeptides B/W receptor type 1 (NPBWR1).	[6]

References

• [1] Schwann cell overexpression of the GPR7 receptor in inflammatory and painful neuropathies.Mol Cell Neurosci. 2005 Jan;28(1):55-63. doi: 10.1016/j.mcn.2004.08.010.
• [2] Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.J Urol. 2007 May;177(5):1753-8. doi: 10.1016/j.juro.2007.01.010.
• [3] Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7.J Hypertens. 2015 Dec;33(12):2431-42. doi: 10.1097/HJH.0000000000000723.
• [4] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [5] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [6] Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer. Arch Med Res. 2014 Aug;45(6):445-54.